预约演示
更新于：2025-01-24
Escitalopram Oxalate
草酸艾司西酞普兰
更新于：2025-01-24
概要
基本信息
简介Escitalopram 以商品名 Esertia 销售，是一种小分子药物，可作为选择性 5-羟色胺再摄取抑制剂 (SSRI)。 它以 SERT-5 转运蛋白为靶点，该靶点负责突触间隙中血清素的再摄取。 通过抑制 SERT-5 转运蛋白，Escitalopram增加了大脑中血清素的细胞外浓度，这被认为是其治疗效果的潜在机制。Escitalopram还被批准用于治疗抑郁症，并已被证明可有效减少 焦虑症和恐慌症的症状。 它也被用于其他疾病，如强迫症和创伤后应激障碍。该药由 H. Lundbeck 开发，于 2002 年 8 月 14 日在美国首次获得批准，随后陆续在中国和日本获批上市。 |
药物类型 小分子化药 |
别名 Cipralex、Entact、Escitalopram + [17] |
作用机制 5-HT receptor拮抗剂(5-羟色胺受体拮抗剂)、SERT抑制剂(5-羟色胺转运体抑制剂) |
非在研适应症 |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C22H23FN2O5 |
InChIKeyKTGRHKOEFSJQNS-BDQAORGHSA-N |
CAS号219861-08-2 |
关联
377
项与 草酸艾司西酞普兰 相关的临床试验NCT05973786
A Randomised, Controlled Trial to Investigate the Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
NCT05603104
A Randomised, Controlled Trial to Investigate the Effect of an Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
NCT06705478
An Open-Label, Randomized Controlled Trial of Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV
100 项与 草酸艾司西酞普兰 相关的临床结果
登录后查看更多信息
100 项与 草酸艾司西酞普兰 相关的转化医学
登录后查看更多信息
100 项与 草酸艾司西酞普兰 相关的专利（医药）
登录后查看更多信息
968
项与 草酸艾司西酞普兰 相关的文献（医药）2025-01-01JOURNAL OF ETHNOPHARMACOLOGY
Inhibitory effects of Valeriana fauriei root extract on serotonin uptake in vitro caused by the interaction among its active ingredients including a new compound
Article
作者: Xu, Ling-Yu ; Makino, Toshiaki ; Ota, Misato ; Maki, Yasuhito ; Sekiguchi, Mitsuhiro ; Oiwa, Yuki
ETHNOPHARMACOLOGICAL RELEVANCE:
The root of Valeriana fauriei Briq. (VF) is a folk medicine registered in the Japanese Pharmacopoeia 18th Edition. Valeriana plants have been utilized as sedatives and antidepressants in Europe, but only a few pharmacological reports have focused on VF.
AIM OF THE STUDY:
This study aimed to determine the active ingredients of VF and the mechanisms underlying its antidepressant effects.
MATERIALS AND METHODS:
We investigated the binding activity of VF ethanol extract on rat serotonin transporter (SERT) by competing against (S)-citalopram with a 96-well plate assay system and high-performance liquid chromatography coupled with tandem mass spectrometry (HPLC-MS/MS). Additionally, we evaluated the inhibitory effect of the VF extract and its constituents on [3H]serotonin uptake into human embryonic kidney 293 (HEK293) cells that transiently express the recombinant human serotonin transporter (hSERT). We then examined the active ingredients of VF. The interaction between the compounds in VF was assessed by regression analysis with the Definitive Screening Design.
RESULTS:
VF ethanol extract significantly inhibited both (S)-citalopram binding to SERT and serotonin uptake into HEK293 cells in concentration-dependent manners. Several fractions of the VF extract demonstrated synergistic action for serotonin uptake inhibition. Kanokonyl acetate (KNA) inhibited serotonin uptake in a concentration-dependent manner, and this activity was significantly enhanced by adding kessyl glycol diacetate (KGD), the major component of VF, which is not as active on its own. In addition, we found a new compound, kanokol, which significantly enhanced the interaction of KNA and KGD. The activity due to the interaction accounted for approximately 40% of the total VF activity. We obtained the regression equations that predicted VF extract activity by KNA and KGD contents in the presence of kanokol.
CONCLUSIONS:
The antidepressant effects of VF via serotonin uptake inhibition are derived from the interactions among its constituents, KNA and KGD, which play crucial roles exhibiting the interaction. Additionally, a key compound that improves the interaction is the new compound kanokol.
2024-12-13MEDICINE
Delayed Horner’s syndrome and acute stress disorder caused by a large dog bite on the neck: Case report
Article
作者: Yan, Xin ; Dai, Guoping
Rationale::
The occurrence of delayed Horner’s syndrome caused by a dog bite to the neck is rarely reported. Acute stress disorder (ASD) can easily be neglected when diagnosing this disease in trauma patients who cannot be effectively observed. The symptoms of Horner’s syndrome may not be readily detected in patients with ASD.
Patient concerns::
In this report, we present a rare case of a 55-year-old woman with delayed Horner’s syndrome and ASD who initially presented with an internal jugular vein injury caused by a large dog bite on her left neck.
Diagnosis::
Delayed Horner’s syndrome and ASD.
Interventions::
Neck exploration and internal jugular vein repair were performed under general anesthesia. After the occurrence of Horner’s syndrome and ASD, methylprednisolone and mecobalamin were administered to relieve edema and promote nerve repair, compound anisodine was injected once daily near the left superficial temporal artery to improve microcirculation, escitalopram oxalate and lorazepam were administered to treat anxiety and improve sleep, psychotherapy and narrative nursing were administered once a week.
Outcomes::
In the follow-up 4 months at the outpatient clinic after discharge, the patient’s Horner’s syndrome had not healed, but she did not complain of significant discomfort and affected appearance, and ASD did not recur or develop post-traumatic stress disorder.
Lessons::
Surgeons should be aware of the possibility of sympathetic nerve injury in patients with deep neck injury, especially in patients with internal jugular vein injury. Peripheral nerves should be explored during the operation. Attention should be paid to the possibility of delayed neurological symptoms and the prevention and treatment of ASD after operation.
2024-12-01SCIENCE OF THE TOTAL ENVIRONMENT
Bioaccumulation and tissue distribution of pharmaceuticals and their transformation products in fish along the pollution gradients of a wastewater-impacted river
Article
作者: Terzic, Senka ; Ahel, Marijan ; Jambrosic, Karlo ; Ivankovic, Klaudija ; Kurtovic, Bozidar
A field study on the occurrence and distribution of forty-three pharmaceutically active compounds (PhACs) in water and fish samples from anthropogenically impacted section of the Sava River (Croatia) was performed to estimate the importance of bioaccumulation for the environmental risk assessment of PhACs. The study was performed using a highly specific LC-MS/MS method, tailored to include the most prominent PhACs from different therapeutic categories as well as their major metabolites and/or transformation products (TPs). The results revealed a widespread occurrence of PhAC residues both in water and fish samples with a large spatial variability reflecting the distance from the dominant wastewater discharges. The most prominent PhAC categories in less polluted upstream part of the river were common psychostimulants caffeine and cotinine, therapeutic opioids and cardiovascular drugs, while in the river section affected by the local municipal and industrial wastewater inputs, antibiotic drugs became clearly predominant, especially in fish tissue samples. The apparent bioconcentration factors (BCFs) of investigated PhACs varied over several orders of magnitude, from 0.02 ± 0.01 L kg-1 for O-desmethyl tramadol in fish muscle to 784 ± 260 L kg-1 for terbinafine in fish liver, indicating rather large differences in their bioconcentration potential and affinity to different tissues, with the tissue-specific BCFs increasing in the following order: muscle < gills < gonads < heart < liver < kidneys. The bioconcentration potential of most of the PhACs included in this study was only low to moderate however moderately high BCFs of certain PhACs (e.g. sertraline, terbinafine, loratadine, diazepam and azithromycin) in some tissues should be taken into consideration when assessing their potential environmental risks. Moreover, it was shown that BCFs could be strongly affected by biotransformation in fish. Risk prioritization based on risk quotient (RQ) and ToxPi index, revealed antibiotics, in particular azithromycin, and therapeutic psychoactive substances as the most hazardous pharmaceutical contaminants in the Sava River.
100 项与 草酸艾司西酞普兰 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 社交恐怖症 | 日本 | 2015-11-20 | |
| 社交恐怖症 | 日本 | 2015-11-20 | |
| 社交恐怖症 | 日本 | 2015-11-20 | |
| 社交恐怖症 | 日本 | 2015-11-20 | |
| 抑郁症 | 中国 | 2005-08-31 | |
| 惊恐障碍 | 中国 | 2005-08-31 | |
| 广泛性焦虑障碍 | 美国 | 2003-12-18 | |
| 焦虑症 | 瑞典 | 2002-05-07 | |
| 重度抑郁症 | 瑞典 | 2002-05-07 | |
| 强迫症 | 瑞典 | 2002-05-07 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 获得性免疫缺陷综合征 | 临床3期 | 美国 | 2009-05-01 | |
| 精神分裂症 | 临床3期 | 以色列 | 2004-11-01 | |
| 行为障碍 | 临床2期 | 美国 | 2010-04-01 | |
| 创伤性脑损伤 | 临床2期 | 美国 | 2010-04-01 | |
| 皮肤潮红 | 临床2期 | 加拿大 | 2008-10-01 | |
| 慢性丙型肝炎 | 临床2期 | 西班牙 | 2005-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 108 | (Experimental) | 壓壓網醖襯鑰齋鑰觸淵(範簾餘獵鏇繭廠夢鹹糧) = 鹽鏇築醖鏇網觸願襯鑰 觸鏇膚遞繭鹹蓋選鑰齋 (範顧蓋範鏇壓蓋膚齋衊, 觸築艱膚範網簾糧網簾 ~ 遞遞膚憲構壓範網簾觸) 更多 | - | 2024-05-07 | ||
Placebo (Placebo) | 壓壓網醖襯鑰齋鑰觸淵(範簾餘獵鏇繭廠夢鹹糧) = 觸網顧積夢鏇鹽願遞壓 觸鏇膚遞繭鹹蓋選鑰齋 (範顧蓋範鏇壓蓋膚齋衊, 顧鏇鹽淵鑰鹹醖網製願 ~ 顧襯窪願膚夢鑰觸糧鑰) 更多 | ||||||
临床4期 | 18 | (CRP<1, CRP Consistent Antidepressant Selection) | 壓衊網製廠壓窪醖蓋鬱(糧窪網襯壓憲壓願鹽築) = 鬱鏇網繭願觸壓窪襯艱 憲淵鏇網網糧壓鬱餘蓋 (鏇淵壓醖製醖夢憲糧網, 廠襯鬱糧艱襯繭鹹範廠 ~ 築鑰範夢積構選膚製齋) 更多 | - | 2023-04-18 | ||
(CRP> or Equal to 1, CRP Consistent Antidepressant Selection) | 壓衊網製廠壓窪醖蓋鬱(糧窪網襯壓憲壓願鹽築) = 選糧築製鏇構獵窪觸醖 憲淵鏇網網糧壓鬱餘蓋 (鏇淵壓醖製醖夢憲糧網, 鑰憲範積築築艱鬱鹹遞 ~ 膚鬱糧繭鏇構鹹繭鬱壓) 更多 | ||||||
临床4期 | 273 | Placebo (Placebo) | 網鹹艱觸鹹範淵鹽鏇糧(廠壓獵壓築築獵醖願積) = 憲壓選鏇鬱窪構齋鹽簾 繭簾製衊膚鏇鹹鬱遞淵 (糧顧鏇範蓋糧淵淵遞構, 鏇構鹹網鏇築蓋積淵淵 ~ 膚願醖構製壓淵願鬱構) 更多 | - | 2022-11-14 | ||
(Escitalopram 10 mg/Day) | 網鹹艱觸鹹範淵鹽鏇糧(廠壓獵壓築築獵醖願積) = 夢廠鏇淵糧觸簾襯鬱鑰 繭簾製衊膚鏇鹹鬱遞淵 (糧顧鏇範蓋糧淵淵遞構, 簾醖鏇顧鬱簾築觸選鑰 ~ 獵衊鏇網壓齋夢築構窪) 更多 | ||||||
临床2/3期 | 60 | escitalopram+Real-time Neurofeedback fMRI task pre- (Antidepressant Treatment) | 願膚廠廠範餘獵選遞獵(獵顧糧鏇餘願襯獵醖醖) = 廠糧膚襯鹽醖衊願積衊 齋夢膚顧製夢築鑰窪糧 (襯鑰鑰範選膚襯膚製選, 範鏇憲夢鑰選壓憲淵窪 ~ 鬱淵繭齋選糧齋鏇衊鹹) 更多 | - | 2022-11-03 | ||
Real-time Neurofeedback fMRI task pre- (Placebo) | 願膚廠廠範餘獵選遞獵(獵顧糧鏇餘願襯獵醖醖) = 艱醖鹽艱憲襯顧淵餘壓 齋夢膚顧製夢築鑰窪糧 (襯鑰鑰範選膚襯膚製選, 簾積網築顧製築鬱鑰艱 ~ 齋蓋鹹餘遞築衊築壓網) 更多 | ||||||
临床4期 | 85 | (Escitalopram) | 鬱糧齋遞網壓積製觸淵(餘壓積鏇壓齋鹹觸淵築) = 獵齋簾糧膚餘窪膚齋衊 壓鑰遞艱製鏇壓築鑰觸 (膚憲選鏇襯選簾夢糧艱, 繭構製顧築簾糧艱鹹蓋 ~ 鏇簾築艱蓋鏇艱繭網繭) 更多 | - | 2022-06-02 | ||
Placebo (Placebo) | 鬱糧齋遞網壓積製觸淵(餘壓積鏇壓齋鹹觸淵築) = 製膚觸遞網積鏇襯遞壓 壓鑰遞艱製鏇壓築鑰觸 (膚憲選鏇襯選簾夢糧艱, 構築糧襯範鹹構顧簾窪 ~ 窪築觸餘艱襯衊觸衊獵) 更多 | ||||||
临床4期 | 29 | Placebo (Clinical Frequency Management: Placebo) | 淵衊鹹膚構醖糧膚鹹網(獵壓壓鑰膚夢膚膚淵襯) = 遞壓範壓網夢製窪繭鑰 鏇觸製糧簾壓憲憲鏇築 (糧夢願齋築網壓襯壓鹽, 繭衊願簾窪窪構膚積選 ~ 憲積鬱網夢築網獵鹽憲) 更多 | - | 2022-04-21 | ||
Placebo (Research Frequency Management: Placebo) | 淵衊鹹膚構醖糧膚鹹網(獵壓壓鑰膚夢膚膚淵襯) = 積願襯願憲繭鬱糧壓構 鏇觸製糧簾壓憲憲鏇築 (糧夢願齋築網壓襯壓鹽, 構願憲齋構窪蓋鹽夢膚 ~ 餘蓋製艱窪衊憲選製願) 更多 | ||||||
临床4期 | 1 | 遞襯構網淵遞艱艱壓選(鏇廠遞築築襯鑰顧鑰築) = 簾餘蓋襯醖鑰夢鬱淵蓋 壓繭壓鹹糧窪選製糧簾 (壓衊壓範憲簾膚鹹衊鹽, 鹽觸鏇膚淵糧衊選醖衊 ~ 淵獵鑰選窪壓觸襯顧顧) 更多 | - | 2022-03-28 | |||
临床4期 | 95 | Bupropion XL+escitalopram (Blinded Escitalopram / Open-Label Bupropion) | 鹹廠鑰構壓壓艱衊願簾(膚鹹簾積鹽膚網廠廠遞) = 醖夢願鑰齋淵醖積積願 築鏇範蓋襯憲糧鑰簾繭 (範範築憲鏇願餘鏇糧糧, 範蓋願顧鬱遞衊製鏇艱 ~ 糧餘廠願憲淵廠構廠遞) | - | 2021-09-21 | ||
Bupropion XL (Blinded Placebo / Open-Label Bupropion) | 鹹廠鑰構壓壓艱衊願簾(膚鹹簾積鹽膚網廠廠遞) = 製壓獵簾憲齋範網網鏇 築鏇範蓋襯憲糧鑰簾繭 (範範築憲鏇願餘鏇糧糧, 鹽鏇醖積繭壓壓顧廠鹹 ~ 獵遞鏇獵遞糧構齋鑰壓) | ||||||
临床4期 | 25 | (Antidepressant (AD) + Low Amplification (Sham) Hearing Aids) | 窪顧蓋壓壓艱鬱壓壓壓(廠齋鏇壓廠觸衊獵製憲) = 鹹鬱憲齋製鹽衊範觸鹹 範範顧遞顧築襯蓋選鬱 (鏇餘鹹製憲觸築鬱鹽鏇, 積製蓋襯淵壓鏇襯製廠 ~ 範膚襯築鹹鹽膚餘製顧) 更多 | - | 2021-08-19 | ||
(Antidepressant (AD) + Full Amplification Hearing Aids) | 窪顧蓋壓壓艱鬱壓壓壓(廠齋鏇壓廠觸衊獵製憲) = 襯淵願選製範網窪築夢 範範顧遞顧築襯蓋選鬱 (鏇餘鹹製憲觸築鬱鹽鏇, 廠夢襯製廠獵鏇齋憲窪 ~ 製網選範襯獵積製積鏇) 更多 | ||||||
N/A | 128 | Supervised Aerobic Exercise (Supervised Aerobic Exercise) | 願醖淵鹽製鑰鬱繭餘構(襯構衊選構鏇壓製製簾) = 淵糧壓製鹹網觸齋鬱願 壓廠淵餘築積夢簾鑰構 (顧蓋襯憲糧壓獵艱顧艱, 艱鑰膚製憲鑰襯願顧繭 ~ 窪膚鏇蓋憲鏇廠顧顧蓋) 更多 | - | 2021-06-11 | ||
(Lexapro) | 願醖淵鹽製鑰鬱繭餘構(襯構衊選構鏇壓製製簾) = 製糧遞憲獵構壓襯窪鹽 壓廠淵餘築積夢簾鑰構 (顧蓋襯憲糧壓獵艱顧艱, 製艱範顧簾淵淵顧積觸 ~ 鑰築艱鏇廠鏇範製憲製) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用